CSE: BUX | OTCQB: BMKDF

BioMark™ Diagnostics

BioMark is proud to announce

  1. NRC – IRAP Funding for 2013 – BioMark will be funded generously by NRC with emphasis on developing prototypes for cancer screening kits using antibodies generated at UBC and IR Raman based technologies currently being developed at UVic.Both systems are targeted for use when the trials are completed at CancerCare Manitoba in 2013.
  2. Engage Grant approval with Dr. Farser Hof of UVic for further chemical method development related to specific material enrichment”. Engage grants are intended to foster the development of new research partnerships between academic researcher and a company.
  3. New Provisional Patents filed New Polyclonal antibodies generated at UBC; Raman IR systems designed at UVic
  4. Funding Approval by Going Global Innovation (GGI) component of the Global Commerce Support Program for joint R&D between National Health Association of China and BioMark Techonogies Inc. for the research and development of a novel non- invasive method to screen and detect cancer using urine. This is good news for the company especially as it targets the developing economies where cancer rates and diagnostic market is expanding rapidly.
  5. New grants applied – decisions to be announced by end of Qtr 1 2013.

Contact BioMark Diagnostics

Canadian Stock Exchange

CSE: BUX
BioMark Diagnostics Inc.
$0.55
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

OTC Markets

OTCQB: BMKDF
BioMark Diagnostics Inc.
$0.40
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

Frankfurt Stock Exchange

FSE: 20B
BioMark Diagnostics Inc.
€0.36
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

Share This Post

Facebook
X
LinkedIn
Reddit
VK
StumbleUpon
Telegram
XING
WhatsApp
Threads
Email
Print

Related News

Sign up for the latest BioMark news